Results 211 to 220 of about 21,694,813 (356)

Translational research targeting inflammatory responses and development of novel drugs

, 2021
Masahiro Nishibori
openalex   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Advancing drug development with "Fit-for-Purpose" modeling informed approaches. [PDF]

J Pharmacokinet Pharmacodyn
Sheng J, Zhang T.
europepmc   +1 more source

Novel approaches to address challenges in global drug development [PDF]

, 2015
BP Smith, Huang Sm
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Iteration of Tumor Organoids in Drug Development: Simplification and Integration. [PDF]

Pharmaceuticals (Basel)
Zhao R, Feng Q, Xia Y, Liao L, Xie S.
europepmc   +1 more source

Development of pharmacogenetics and clinical pharmacology. From molecular level to clinical medicine and drug development. Clinical significance of phenotyping and genotyping.

, 1996
Frank J. Gonzalez
openalex   +2 more sources

[Progress and Application of Bayesian Approach in the Early Research and Development of New Anticancer Drugs].

, 2022
Huiyao Huang, Meiruo Liu, Xiyan Li, Xinyu Meng, Dandan Cui, Ye Leng, Yu Tang, Ning Li   +7 more
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Software-Enhanced Drugs™: The third platform reshaping drug development. [PDF]

Proc Natl Acad Sci U S A
Lakhan SE, Wicks P.
europepmc   +1 more source